STOCK TITAN
  1. Home
  2. Sec-filings
  3. LFCR
  4. [Form 4] LIFECORE BIOMEDICAL, INC. DE Insider Trading Activity

Lifecore (NASDAQ: LFCR) executive RSU vesting leads to 24,645 shares withheld for tax

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Lifecore Biomedical executive Thomas D. Salus reported a routine tax-related share disposition. On April 14, 2026, 24,645 shares of common stock were withheld by the company at $5.20 per share to cover tax obligations from vesting restricted stock units. After this withholding, Salus directly owned 246,333 shares of Lifecore Biomedical common stock, indicating he retained a substantial equity position and that no open-market sale occurred.

Positive

  • None.

Negative

  • None.
Insider Salus Thomas D.
Role Chief Legal & Administration
Type Security Shares Price Value
Tax Withholding Common Stock 24,645 $5.20 $128K
Holdings After Transaction: Common Stock — 246,333 shares (Direct)
Footnotes (1)
  1. [object Object]
Tax-withholding shares 24,645 shares Shares withheld to satisfy tax obligations on RSU vesting
Withholding price $5.20 per share Price applied to the 24,645 withheld shares
Shares owned after transaction 246,333 shares Direct holdings of Thomas D. Salus following withholding
RSU financial
"in connection with the vesting and settlement of an RSU vesting"
Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.
tax withholding obligations financial
"withheld by the issuer to satisfy applicable tax withholding obligations"
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
Common Stock financial
""security_title": "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Salus Thomas D.
(Last)(First)(Middle)
C/O LIFECORE BIOMEDICAL, INC.
3515 LYMAN BLVD.
(Street)
CHASKA MINNESOTA 55318
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
LIFECORE BIOMEDICAL, INC. \DE\ [ LFCR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Legal & Administration
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/14/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/14/2026F24,645(1)D$5.2246,333D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of an RSU vesting.
Remarks:
/s/ Aaron S. Perlitsh, Attorney-In-Fact for Thomas D Salus04/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did LFCR executive Thomas D. Salus report?

Thomas D. Salus reported a tax-withholding disposition of shares. The company withheld 24,645 shares of Lifecore Biomedical common stock to satisfy tax obligations tied to vesting restricted stock units, rather than an open-market sale by the executive.

Was the Lifecore Biomedical (LFCR) Form 4 transaction a stock sale?

The Form 4 transaction was not an open-market stock sale. Lifecore Biomedical withheld 24,645 shares from Thomas D. Salus at $5.20 per share to cover tax liabilities on RSU vesting, a common administrative mechanism for equity compensation.

How many LFCR shares does Thomas D. Salus hold after this Form 4 event?

After the reported tax-withholding event, Thomas D. Salus directly owned 246,333 shares of Lifecore Biomedical common stock. This figure reflects his remaining equity position following the 24,645 shares withheld to satisfy associated tax obligations on RSU vesting.

What price per share was used for the LFCR tax-withholding disposition?

The tax-withholding disposition used a price of $5.20 per share. Lifecore Biomedical applied this price when withholding 24,645 shares from Thomas D. Salus to meet his tax obligations related to the vesting and settlement of restricted stock units.